EU Biotech Act & Clinical Trials
How can the Act accelerate early access for patients?
1 July 2026 | 10:00 – 11:30 CEST
The EU Biotech Act is set to play a pivotal role in shaping the future of clinical trials and accelerating access to innovative cancer treatments across Europe. Join us on 1 July as EU policymakers, clinical research experts, industry leaders and patient advocates come together to explore how the Biotech Act can help shape a patient-centred clinical trials framework that enhances participation, promotes inclusiveness, and ensures more equitable access to clinical research opportunities across Europe. This webinar is part of CPE’s 2026 Policy Webinar Series and offers a unique opportunity to explore how Europe’s biotech agenda can deliver real benefits for cancer patients.
Why This Webinar Matters
The EU Biotech Act is set to become a cornerstone of Europe’s strategy to strengthen biotechnology, foster the development of innovative health solutions, and create a more supportive environment for clinical research and clinical trials. As the legislative process moves forward, it is crucial to ensure that patients are not only beneficiaries of innovation but active contributors to the policies that shape it. Bringing patients’ lived experience into this process is essential to ensuring the Act delivers where it matters most. For cancer patients, clinical trials are often the gateway to cutting-edge treatments and sometime the only available treatment option, yet access remains uneven across Europe. This webinar provides a timely opportunity to examine how the EU Biotech Act can better support patient needs and ensure that innovation leads to tangible improvements in care.
What We Aim to Achieve
This webinar aims to equip patient organisations and stakeholders with a clearer understanding of the EU Biotech Act and its potential impact on clinical research and innovation pathways. Through expert discussion and stakeholder exchange, participants will explore practical solutions to improve the accessibility, inclusiveness, and relevance of clinical trials, while identifying priorities for future policy engagement. The conversation will also contribute to developing recommendations that help ensure Europe’s biotechnology ambitions translate into better outcomes and opportunities for patients.
WITH THE FINANCIAL SUPPORT OF
